This may be attributed to the fact that, unlike dupilumab, tralokinumab does not inhibit IL-4 signaling pathways, making Th17 hyperactivation less likely and thereby reducing hyperactivated inflammation toward fungal infections [19]. This evidence concerns the gene IL4 and fungal infectious disease.